PRTA

ProthenaC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

Current thesis

PRTA has unusually strong balance-sheet support for a company of its size: year-end 2025 cash was $308.4 million, 2026 year-end cash guidance was about $255 million before additional partner milestones, and the March Novo milestone plus buyback authorization improve the capital-allocation story [#IR-2026-02-19] [#IR-2026-03-09] [#8-K-2026-02-27].

Posture

Mixed

Lead driver

Sentiment

What changed

Sentiment remains the lead driver in the composite, 7D delta +6.7.

What can break

PRX019 advancement could be delayed or declined by Bristol Myers Squibb.

Momentum

Value

Sentiment

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $12.50 · Bull $16.00 · Bear $7.25

Data freshness

Prices

As of 2026-06-02

Fundamentals

As of 2026-06-01 • Vendor: Data Vendor v1

Scores

As of 2026-06-02 • Model: HYBRID_IC_RP

AI Memo

As of 2026-04-17 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-06-02

Supporting evidence

What

Grade C · Mixed

Confidence Medium · Net Neutral

Target $20.50

Why

Momentum29 · Δ7d -9.7

Value41 · Δ7d +0.1

Sentiment81 · Δ7d +6.7

So what

Balanced signals (Net Neutral). Wait for confirmation before sizing up.

Lead driver: Sentiment · See AI snapshot

Momentum

34% active weight

Current posture

7d trendSoftening

Δ7d

-9.7

Δ21d

-37.6

Value

32% active weight

Current posture

7d trendFlat

Δ7d

+0.1

Δ21d

+0.2

Sentiment

33% active weight

Current posture

7d trendImproving

Δ7d

+6.7

Δ21d

+10.3

Why this grade

Composite grade C. Momentum 28.8 / Value 41.1 / Sentiment 80.6

Fundamentals (TTM)

As of 2026-06-01

Market Cap

$502.07M

Beta

-0.11

Shares Out

53.83M

P/E (TTM) · Derived

-2.1

P/S (TTM)

41.56

P/FCF (TTM) · Derived

-2.67

Rev YoY

+149.0%

EPS YoY

+38.1%

Gross Margin

Op Margin

-2166.4%

Net Debt

-$471.39M

Current Ratio

6.61

As of 2026-06-02 • Updated nightlySource: Internal modelMethodology